Improving Patient Outcomes in Psoriasis: Strategies to Ensure Treatment Adherence

Overview

Journal Psoriasis (Auckl)

Publisher Dove Medical Press

Date 2018 Feb 2

PMID 29387587

Citations 9

Authors

Oriol Yelamos

Sandra Ros

Lluis Puig

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a frequent inflammatory disease with a chronic and relapsing course. Therefore, patients with psoriasis are likely to undergo different treatments for long periods of time. Traditionally, therapies used in psoriasis have been associated with poor levels of adherence due to the complexity of the regimens and the poor results obtained with the topical therapies. These poor outcomes are associated with high levels of frustration and anxiety, which decrease adherence and worsen the disease. With the recent introduction of highly efficacious biologic therapies, patients can achieve very good and prolonged responses. However, most patients with psoriasis have mild disease and may be treated with skin-directed therapies. Therefore, it is important to develop strategies to improve adherence in order to achieve better outcomes, and to improve the overall quality of life. Hence, acknowledging the causes of nonadherence is crucial for implementing these strategies. In this summary, we review the causes of nonadherence, and we provide behavioral strategies in order to improve adherence and, ultimately, the outcome of patients with psoriasis.

Citing Articles

Factors Associated with Anxiety, Depression, and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study.

Cipolla S, Catapano P, Bonamico A, De Santis V, Murolo R, Romano F Brain Sci. 2024; 14(9).

PMID: 39335361 PMC: 11430425. DOI: 10.3390/brainsci14090865.

Influence of Clinical and Psychosocial Factors on the Adherence to Topical Treatment in Psoriasis.

Teixeira A, Teixeira M, Gaio R, Torres T, Magina S, Dinis M Healthcare (Basel). 2024; 12(8).

PMID: 38667584 PMC: 11050139. DOI: 10.3390/healthcare12080822.

Modeling Posttreatment Prognosis of Skin Lesions in Patients With Psoriasis in China.

Yang Z, Han S, Wu P, Wang M, Li R, Zhou X JAMA Netw Open. 2023; 6(4):e236795.

PMID: 37022681 PMC: 10080370. DOI: 10.1001/jamanetworkopen.2023.6795.

The use of SCL-k-9 to measure general psychopathology in women and men with skin conditions.

Samela T, Cordella G, Antinone V, Sarandrea P, Giampetruzzi A, Abeni D Front Psychol. 2022; 13:977264.

PMID: 36337481 PMC: 9632958. DOI: 10.3389/fpsyg.2022.977264.

Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.

Tada Y, Kim H, Spanopoulos D, Habiro K, Tsuritani K, Yamada Y J Dermatol. 2022; 49(11):1106-1117.

PMID: 35946343 PMC: 9804179. DOI: 10.1111/1346-8138.16543.

References

Feldman S . Approaching psoriasis differently: patient-physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol. 2010; 9(8):908-11. View

Storm A, Benfeldt E, Andersen S, Serup J . A prospective study of patient adherence to topical treatments: 95% of patients underdose. J Am Acad Dermatol. 2008; 59(6):975-80. DOI: 10.1016/j.jaad.2008.07.039. View

Menter A, Korman N, Elmets C, Feldman S, Gelfand J, Gordon K . Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009; 61(3):451-85. DOI: 10.1016/j.jaad.2009.03.027. View

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

Zaghloul S, Goodfield M . Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004; 140(4):408-14. DOI: 10.1001/archderm.140.4.408. View

Aronson J . Compliance, concordance, adherence. Br J Clin Pharmacol. 2007; 63(4):383-4. PMC: 2203247. DOI: 10.1111/j.1365-2125.2007.02893.x. View

Chapman B, Moynihan J . The brain-skin connection: role of psychosocial factors and neuropeptides in psoriasis. Expert Rev Clin Immunol. 2010; 5(6):623-7. PMC: 2926975. DOI: 10.1586/eci.09.56. View

Storm A, Andersen S, Benfeldt E, Serup J . One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008; 59(1):27-33. DOI: 10.1016/j.jaad.2008.03.045. View

Ali S, Brodell R, Balkrishnan R, Feldman S . Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol. 2007; 143(7):912-5. DOI: 10.1001/archderm.143.7.912. View

10.

Ersser S, Surridge H, Wiles A . What criteria do patients use when judging the effectiveness of psoriasis management?. J Eval Clin Pract. 2002; 8(4):367-76. DOI: 10.1046/j.1365-2753.2002.00372.x. View

11.

Goldberg D, Bridges K, Grayson D . Detecting anxiety and depression in general medical settings. BMJ. 1988; 297(6653):897-9. PMC: 1834427. DOI: 10.1136/bmj.297.6653.897. View

12.

McAleer M, Mason D, Cunningham S, OShea S, McCormick P, Stone C . Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. Br J Dermatol. 2011; 164(6):1256-61. DOI: 10.1111/j.1365-2133.2011.10345.x. View

13.

Kimball A, Jacobson C, Weiss S, Vreeland M, Wu Y . The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005; 6(6):383-92. DOI: 10.2165/00128071-200506060-00005. View

14.

Kardas P, Lewek P, Matyjaszczyk M . Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013; 4:91. PMC: 3722478. DOI: 10.3389/fphar.2013.00091. View

15.

Baker C, Foley P, Braue A . Psoriasis uncovered--measuring burden of disease impact in a survey of Australians with psoriasis. Australas J Dermatol. 2013; 54 Suppl 1:1-6. DOI: 10.1111/ajd.12010. View

16.

Bhatti Z, Finlay A, Bolton C, George L, Halcox J, Jones S . Chronic disease influences over 40 major life-changing decisions (MLCDs): a qualitative study in dermatology and general medicine. J Eur Acad Dermatol Venereol. 2013; 28(10):1344-55. DOI: 10.1111/jdv.12289. View

17.

Fortune D, Richards H, Kirby B, Bowcock S, Main C, Griffiths C . A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. Br J Dermatol. 2002; 146(3):458-65. DOI: 10.1046/j.1365-2133.2002.04622.x. View

18.

Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke M . Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011; 222(4):363-74. DOI: 10.1159/000329026. View

19.

Warino L, Balkrishnan R, Feldman S . Clobetasol propionate for psoriasis: are ointments really more potent?. J Drugs Dermatol. 2006; 5(6):527-32. View

20.

Ortonne J, Chimenti S, Luger T, Puig L, Reid F, Trueb R . Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol. 2009; 23(12):1435-44. DOI: 10.1111/j.1468-3083.2009.03372.x. View